Our VP Technology Assessment, Maarten Brom, and Business to Science Manager, Famke Van Renesse-Brouwer, will represent TRACER and participate in the meetings at the annual congress of the European Association of Nuclear Medicine.
For you as a drug developer, this is a great chance to explore opportunities for fast-track clinical trials. Fill out the contact form on this page, to schedule your meeting with us.
We are excited to meet you in Hamburg!
Phase 0 data points
We like to share the most important data points on Phase 0 clinical trials. In our meeting we will elaborate on this and there will be time to answer questions regarding clinical trials for your compound.
- Approved method by FDA and EMA
- Up to a 73% higher chance of success in subsequent trials
- First patient in within 6 months
- On- /off-target data in approximately 12 months
- GLP material is sufficient
- Only limited toxicity studies needed
- Skip large animal studies
- Significantly lower investment in comparison to Phase I
Fill out the form on this page to schedule your meeting at the EANM congress, or send an e-mail to info@tracercro.com.